Brokerage firm UBS Maintains its rating on AtriCure(NASDAQ:ATRC). In a research note issued to the investors, the brokerage major Lowers the price-target to $14.00 per share. The shares have been rated Sell. The rating by UBS was issued on Aug 5, 2016.
In a different note, JMP Securities said it Initiates Coverage on AtriCure, according to a research note issued on Jun 30, 2016. The shares have been rated ‘Outperform’ by the firm.
AtriCure (ATRC) shares turned negative on Wednesdays trading session with the shares closing down -0.82 points or -5.22% at a volume of 1,72,546. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $15.72. The peak price level was also seen at $15.72 while the days lowest was $14.84. Finally the shares closed at $14.9. The 52-week high of the shares is $27.74 while the 52-week low is $13.44. According to the latest information available, the market cap of the company is $495 M.
AtriCure(ATRC) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $39.67M. Analysts had an estimated revenue of $39.84M. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.30.
Several Insider Transactions has been reported to the SEC. On Mar 9, 2016, Elizabeth D Krell (director) sold 10,000 shares at $16.91 per share price.Also, On Dec 7, 2015, Douglas J Seith (Chief Operating Officer) sold 5,000 shares at $21.55 per share price.On May 8, 2015, Karen P Robards (director) sold 2,650 shares at $22.18 per share price, according to the Form-4 filing with the securities and exchange commission.
AtriCure Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System which includes its Isolator Synergy clamps generator and switchbox is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies including its Lumitip dissectors and Endoscopic Technologies Inc.’s (Estech) line of reusable cardiac surgery instruments.